EA200970090A1 - Модуляторы метаболизма и лечение связанных с ним расстройств - Google Patents
Модуляторы метаболизма и лечение связанных с ним расстройствInfo
- Publication number
- EA200970090A1 EA200970090A1 EA200970090A EA200970090A EA200970090A1 EA 200970090 A1 EA200970090 A1 EA 200970090A1 EA 200970090 A EA200970090 A EA 200970090A EA 200970090 A EA200970090 A EA 200970090A EA 200970090 A1 EA200970090 A1 EA 200970090A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- related disorders
- metabolism modulators
- modulators
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Настоящее изобретение относится к изопропиловому эфиру 4-[6-(6-метансульфонил-2-метилпиридин-3-иламино)-5-метилпиримидин-4-илокси]пиперидин-1-карбоновой кислоты, его фармацевтически приемлемым солям, сольватам и гидратам, которые являются модуляторами метаболизма глюкозы. Соответственно, соединения по настоящему изобретению пригодны для лечения связанных с метаболизмом расстройств и их осложнений, таких как диабет и ожирение.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81950006P | 2006-07-06 | 2006-07-06 | |
PCT/US2007/015681 WO2008005576A1 (en) | 2006-07-06 | 2007-07-05 | Modulators of metabolism and the treatment of disorders related thereto |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200970090A1 true EA200970090A1 (ru) | 2009-06-30 |
EA015343B1 EA015343B1 (ru) | 2011-06-30 |
Family
ID=38707392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200970090A EA015343B1 (ru) | 2006-07-06 | 2007-07-05 | Модуляторы метаболизма и лечение связанных с ним расстройств |
Country Status (26)
Country | Link |
---|---|
US (1) | US20100004272A1 (ru) |
EP (1) | EP2049523A1 (ru) |
JP (1) | JP2009542702A (ru) |
KR (1) | KR20090024779A (ru) |
CN (1) | CN101484440A (ru) |
AR (1) | AR061967A1 (ru) |
AU (1) | AU2007269577A1 (ru) |
BR (1) | BRPI0714006A2 (ru) |
CA (1) | CA2656520A1 (ru) |
CL (1) | CL2007001972A1 (ru) |
CO (1) | CO6160320A2 (ru) |
CR (1) | CR10538A (ru) |
EA (1) | EA015343B1 (ru) |
EC (1) | ECSP099036A (ru) |
GT (1) | GT200800305A (ru) |
IL (1) | IL195819A0 (ru) |
MA (1) | MA30601B1 (ru) |
MX (1) | MX2008016251A (ru) |
NI (1) | NI200800328A (ru) |
NO (1) | NO20090590L (ru) |
PE (1) | PE20080737A1 (ru) |
TN (1) | TNSN08534A1 (ru) |
TW (1) | TW200811140A (ru) |
UY (1) | UY30466A1 (ru) |
WO (1) | WO2008005576A1 (ru) |
ZA (1) | ZA200900051B (ru) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
DK1599468T3 (da) | 2003-01-14 | 2008-02-04 | Arena Pharm Inc | 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi |
AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
EA030606B1 (ru) | 2006-05-04 | 2018-08-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Способы приготовления лекарственного средства, содержащего полиморфы |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
BRPI0817211A2 (pt) | 2007-09-20 | 2017-05-16 | Irm Llc | composto composições como moduladores da atividade de gpr119 |
PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
EP2344195A2 (en) * | 2008-09-10 | 2011-07-20 | Boehringer Ingelheim International GmbH | Combination therapy for the treatment of diabetes and related conditions |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
WO2010059384A1 (en) * | 2008-10-30 | 2010-05-27 | Janssen Pharmaceutica Nv | Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists |
BRPI0923121A2 (pt) | 2008-12-23 | 2015-08-11 | Boehringer Ingelheim Int | Formas salinas de compostos orgânico |
TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
US8410089B2 (en) | 2009-02-18 | 2013-04-02 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring compound |
AU2010264720A1 (en) | 2009-06-24 | 2011-12-08 | Boehringer Ingelheim International Gmbh | New compounds, pharmaceutical composition and methods relating thereto |
WO2010149685A1 (en) | 2009-06-24 | 2010-12-29 | Boehringer Ingelheim International Gmbh | New compounds, pharmaceutical composition and methods relating thereto |
US8886788B2 (en) * | 2009-08-31 | 2014-11-11 | Accenture Global Services Limited | Enterprise-level management, control and information aspects of cloud console |
ES2760917T3 (es) | 2009-11-27 | 2020-05-18 | Boehringer Ingelheim Int | Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina |
ES2937386T3 (es) | 2010-01-27 | 2023-03-28 | Arena Pharm Inc | Procesos para la preparación de ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3-il)acético y sales del mismo |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US20130109703A1 (en) | 2010-03-18 | 2013-05-02 | Boehringer Ingelheim International Gmbh | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions |
JP6034781B2 (ja) | 2010-05-05 | 2016-11-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 併用療法 |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
EA201991014A1 (ru) | 2010-06-24 | 2019-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Лечение диабета |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
WO2012025811A1 (en) | 2010-08-23 | 2012-03-01 | Lupin Limited | Indolylpyrimidines as modulators of gpr119 |
SG188548A1 (en) | 2010-09-22 | 2013-04-30 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
EP2643311A1 (en) | 2010-11-26 | 2013-10-02 | Lupin Limited | Bicyclic gpr119 modulators |
AU2012267556B9 (en) | 2011-06-09 | 2017-05-11 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of GPR-119 |
MX366629B (es) | 2011-07-15 | 2019-07-17 | Boehringer Ingelheim Int | Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas. |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
US9755858B2 (en) * | 2014-04-15 | 2017-09-05 | Cisco Technology, Inc. | Programmable infrastructure gateway for enabling hybrid cloud services in a network environment |
EP3242666A1 (en) | 2015-01-06 | 2017-11-15 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
CN104788424A (zh) * | 2015-03-12 | 2015-07-22 | 佛山市赛维斯医药科技有限公司 | 含烟酸酰胺和哌啶结构的ptp1b抑制剂、制备方法及其用途 |
CN104725310A (zh) * | 2015-03-12 | 2015-06-24 | 佛山市赛维斯医药科技有限公司 | 一种含烟酸酰胺和苯胺结构的ptp1b抑制剂及其用途 |
CN104725309A (zh) * | 2015-03-12 | 2015-06-24 | 佛山市赛维斯医药科技有限公司 | 一种含烟酸酰胺结构的ptp1b抑制剂及其用途 |
CN106831561A (zh) * | 2015-03-12 | 2017-06-13 | 佛山市赛维斯医药科技有限公司 | 一种含烟酸酰胺和苯胺结构的ptp1b抑制剂、其制备及用途 |
CN104725355A (zh) * | 2015-03-12 | 2015-06-24 | 佛山市赛维斯医药科技有限公司 | 一种含烟酸酰胺和哌啶结构ptp1b抑制剂及其用途 |
CN104788425A (zh) * | 2015-03-12 | 2015-07-22 | 佛山市赛维斯医药科技有限公司 | 一类含烟酸酰胺和哌啶结构ptp1b抑制剂、制备方法及其用途 |
CN106831562A (zh) * | 2015-03-12 | 2017-06-13 | 佛山市赛维斯医药科技有限公司 | 含烟酸酰胺结构的ptp1b抑制剂及其用途 |
CN106866523A (zh) * | 2015-03-12 | 2017-06-20 | 佛山市赛维斯医药科技有限公司 | 含烟酸酰胺结构的ptp1b抑制剂、制备方法及其用途 |
CN104725306A (zh) * | 2015-03-12 | 2015-06-24 | 佛山市赛维斯医药科技有限公司 | 一类含烟酸酰胺结构的ptp1b抑制剂、制备方法及其用途 |
CN106831559A (zh) * | 2015-03-12 | 2017-06-13 | 佛山市赛维斯医药科技有限公司 | 一种含烟酸酰胺结构的ptp1b抑制剂、制备方法及其用途 |
CN104761540A (zh) * | 2015-03-12 | 2015-07-08 | 佛山市赛维斯医药科技有限公司 | 一种含烟酸酰胺和哌啶结构的化合物及其用途 |
JP6838744B2 (ja) | 2015-06-22 | 2021-03-03 | アリーナ ファーマシューティカルズ, インコーポレイテッド | S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩 |
JP2019517542A (ja) | 2016-06-10 | 2019-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | リナグリプチンおよびメトホルミンの組合せ |
KR20190116416A (ko) | 2017-02-16 | 2019-10-14 | 아레나 파마슈티칼스, 인크. | 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법 |
CN107145725A (zh) * | 2017-04-26 | 2017-09-08 | 江南大学 | 一种分析餐厨垃圾厌氧消化产甲烷能力的方法 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH499528A (de) * | 1965-10-22 | 1970-11-30 | Ciba Geigy Ag | Verfahren zur Herstellung neuer Pyrimidine |
CH480410A (de) * | 1967-01-09 | 1969-10-31 | Geigy Ag J R | Verfahren zur Herstellung von wasserlöslichen Azopyrimidinfarbstoffen |
CA961052A (en) * | 1967-01-12 | 1975-01-14 | Max Schellenbaum | N-2-ethylhexyl-n'-aryl ureas and preparation containing them |
US3608087A (en) * | 1968-06-21 | 1971-09-21 | Merck & Co Inc | Feed compositions |
US3887329A (en) * | 1969-05-05 | 1975-06-03 | Ciba Geigy Ag | Hexamethyl phosphotriamide-dye compositions |
US3686238A (en) * | 1970-01-19 | 1972-08-22 | Syntex Corp | Glycerol esterified with 2-naphthyl-acetic acids and fatty acids |
US3852434A (en) * | 1970-09-11 | 1974-12-03 | Merck & Co Inc | Potentiation of ({31 ) cis-1,2-epoxypropyl)phosphonic acid and analogues thereof |
US3690834A (en) * | 1971-01-11 | 1972-09-12 | Syva Co | Ligand determination with spin labeled compounds by receptor displacement |
US3966744A (en) * | 1971-01-11 | 1976-06-29 | Syva Company | Spin labeled compounds |
DE2106585A1 (de) * | 1971-02-11 | 1972-08-24 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Aminothiodiazole und Thiodiazol-Azofarbstoffe |
US3966764A (en) * | 1972-07-10 | 1976-06-29 | Syva Company | Ligand determination of spin labeled compounds by receptor displacement-amphetamine analogs |
US3849420A (en) * | 1972-10-20 | 1974-11-19 | Dow Chemical Co | Bis-(alkylthio-and alkylsulfonyl)-pentachloroquinolines |
CH574206A5 (ru) * | 1972-11-16 | 1976-04-15 | Ciba Geigy Ag | |
DE2340569C2 (de) * | 1973-08-10 | 1982-12-02 | Bayer Ag, 5090 Leverkusen | Azofarbstoffe |
AT340933B (de) * | 1973-08-20 | 1978-01-10 | Thomae Gmbh Dr K | Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze |
US4101541A (en) * | 1973-12-21 | 1978-07-18 | Ciba-Geigy Corporation | 3-Cyano-1,2,4-thiadiazolyl-5-czo dyestuffs |
FR2306697A1 (fr) * | 1975-04-10 | 1976-11-05 | Sogeras | Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants |
DE2731264A1 (de) * | 1977-07-11 | 1979-02-01 | Boehringer Mannheim Gmbh | Neue 1-acyl-2-cyanaziridine, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zubereitungen |
JPS6038696B2 (ja) * | 1977-12-09 | 1985-09-02 | コニカ株式会社 | ハロゲン化銀カラ−写真感光材料 |
US4242507A (en) * | 1978-02-23 | 1980-12-30 | Fujisawa Pharmaceutical Co., Ltd. | Sulfonic acid esters |
DE2831580C2 (de) * | 1978-07-18 | 1980-09-18 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren und Reagens zur Bestimmung von Glycerin |
DE2906603A1 (de) * | 1979-02-21 | 1980-09-04 | Boehringer Mannheim Gmbh | N-substituierte aziridin-2-carbonsaeurederivate, verfahren zu deren herstellung sowie diese substanzen enthaltende arzneimittel |
DOP1981004033A (es) * | 1980-12-23 | 1990-12-29 | Ciba Geigy Ag | Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas. |
DE3334455A1 (de) * | 1983-03-04 | 1984-09-06 | Bayer Ag, 5090 Leverkusen | Guanidin - derivate |
ZA848275B (en) * | 1983-12-28 | 1985-08-28 | Degussa | New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring |
DE3601196A1 (de) * | 1986-01-17 | 1987-07-23 | Merck Patent Gmbh | 1,4-dihydropyridine |
US5364865A (en) * | 1992-12-30 | 1994-11-15 | Sterling Winthrop Inc. | Phenoxy- and phenoxyalkyl-piperidines as antiviral agents |
TW530047B (en) * | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
US5945426A (en) * | 1994-09-09 | 1999-08-31 | Nippon Shinyaku Co., Ltd. | Derivatives of pyrimidine for treating acute cerebrovascular disorders |
US5691364A (en) * | 1995-03-10 | 1997-11-25 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
US6956047B1 (en) * | 1995-06-06 | 2005-10-18 | Pfizer Inc. | Corticotropin releasing factor antagonists |
US6403599B1 (en) * | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
US5849759A (en) * | 1995-12-08 | 1998-12-15 | Berlex Laboratories, Inc. | Naphthyl-substituted benzimidazole derivatives as anti-coagulants |
US5948786A (en) * | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
AR008789A1 (es) * | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
US6008234A (en) * | 1996-09-12 | 1999-12-28 | Berlex Laboratories, Inc. | Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants |
US6187777B1 (en) * | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
US6239126B1 (en) * | 1998-12-17 | 2001-05-29 | American Home Products Corporation | Arylpiperidine and aryl-1,2,5,6-tetra-hydropyridine urea derivatives |
US6414002B1 (en) * | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
US6525064B1 (en) * | 2000-12-08 | 2003-02-25 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
US6545016B1 (en) * | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
US6545017B1 (en) * | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
DK1599468T3 (da) * | 2003-01-14 | 2008-02-04 | Arena Pharm Inc | 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi |
CN1751038A (zh) * | 2003-02-24 | 2006-03-22 | 艾尼纳制药公司 | 作为葡萄糖代谢调节剂的经取代芳基和杂芳基衍生物及葡萄糖代谢失调的预防和治疗 |
US7083933B1 (en) * | 2003-05-09 | 2006-08-01 | Prosidion Limited | Methods for identification of modulators of OSGPR116 activity |
AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
EP2287166A3 (en) * | 2003-07-14 | 2011-06-22 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
DK1756084T3 (da) * | 2004-06-04 | 2009-03-23 | Arena Pharm Inc | Substituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser beslægtet dermed |
MY148521A (en) * | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
-
2007
- 2007-07-02 TW TW096124027A patent/TW200811140A/zh unknown
- 2007-07-04 PE PE2007000858A patent/PE20080737A1/es not_active Application Discontinuation
- 2007-07-05 JP JP2009518404A patent/JP2009542702A/ja not_active Withdrawn
- 2007-07-05 CN CNA2007800249135A patent/CN101484440A/zh not_active Withdrawn
- 2007-07-05 CL CL200701972A patent/CL2007001972A1/es unknown
- 2007-07-05 EP EP07810288A patent/EP2049523A1/en not_active Withdrawn
- 2007-07-05 AU AU2007269577A patent/AU2007269577A1/en not_active Withdrawn
- 2007-07-05 EA EA200970090A patent/EA015343B1/ru not_active IP Right Cessation
- 2007-07-05 BR BRPI0714006-1A patent/BRPI0714006A2/pt not_active IP Right Cessation
- 2007-07-05 MX MX2008016251A patent/MX2008016251A/es not_active Application Discontinuation
- 2007-07-05 US US12/307,545 patent/US20100004272A1/en not_active Abandoned
- 2007-07-05 CA CA002656520A patent/CA2656520A1/en not_active Abandoned
- 2007-07-05 KR KR1020097000109A patent/KR20090024779A/ko not_active Application Discontinuation
- 2007-07-05 WO PCT/US2007/015681 patent/WO2008005576A1/en active Application Filing
- 2007-07-06 UY UY30466A patent/UY30466A1/es unknown
- 2007-07-06 AR ARP070103026A patent/AR061967A1/es unknown
-
2008
- 2008-12-09 IL IL195819A patent/IL195819A0/en unknown
- 2008-12-15 NI NI200800328A patent/NI200800328A/es unknown
- 2008-12-19 CR CR10538A patent/CR10538A/es not_active Application Discontinuation
- 2008-12-24 CO CO08136751A patent/CO6160320A2/es unknown
- 2008-12-25 TN TNP2008000534A patent/TNSN08534A1/en unknown
- 2008-12-29 GT GT200800305A patent/GT200800305A/es unknown
-
2009
- 2009-01-05 ZA ZA200900051A patent/ZA200900051B/xx unknown
- 2009-01-06 EC EC2009009036A patent/ECSP099036A/es unknown
- 2009-01-27 MA MA31590A patent/MA30601B1/fr unknown
- 2009-02-06 NO NO20090590A patent/NO20090590L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2656520A1 (en) | 2008-01-10 |
KR20090024779A (ko) | 2009-03-09 |
CN101484440A (zh) | 2009-07-15 |
CO6160320A2 (es) | 2010-05-20 |
ZA200900051B (en) | 2010-01-27 |
JP2009542702A (ja) | 2009-12-03 |
UY30466A1 (es) | 2008-02-29 |
AR061967A1 (es) | 2008-08-10 |
TNSN08534A1 (en) | 2010-04-14 |
BRPI0714006A2 (pt) | 2012-12-18 |
EP2049523A1 (en) | 2009-04-22 |
CL2007001972A1 (es) | 2008-04-04 |
MX2008016251A (es) | 2009-02-25 |
GT200800305A (es) | 2009-04-25 |
IL195819A0 (en) | 2009-09-22 |
EA015343B1 (ru) | 2011-06-30 |
AU2007269577A1 (en) | 2008-01-10 |
WO2008005576A1 (en) | 2008-01-10 |
ECSP099036A (es) | 2009-02-27 |
CR10538A (es) | 2009-01-27 |
PE20080737A1 (es) | 2008-06-13 |
NI200800328A (es) | 2010-01-07 |
TW200811140A (en) | 2008-03-01 |
US20100004272A1 (en) | 2010-01-07 |
MA30601B1 (fr) | 2009-07-01 |
NO20090590L (no) | 2009-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200970090A1 (ru) | Модуляторы метаболизма и лечение связанных с ним расстройств | |
EA200970088A1 (ru) | Модуляторы метаболизма и лечение связанных с ним нарушений | |
EA200800834A1 (ru) | Модуляторы метаболизма и лечение связанных с ним нарушений | |
UA96441C2 (ru) | Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением | |
WO2009117421A3 (en) | Heterocyclic modulators of gpr119 for treatment of disease | |
NO20091605L (no) | Pyridinonforbindelser | |
NO20091700L (no) | Florizinanaloger som inhibitorer av glukose-ko-transporter 2 | |
UA92150C2 (ru) | Замещенные производные арила и гетероарила как модуляторы метаболизма и для профилактики и лечения связанных с ним расстройств | |
NO20083568L (no) | Hydantoinforbindelser for behandling av inflammatoriske forstyrrelser | |
WO2008033562A3 (en) | Kinase inhibitor compounds | |
EA200701471A1 (ru) | Замещённые пиридинильные и пиримидинильные производные, используемые в качестве модуляторов метаболизма и лечение ассоциированных с ним расстройств | |
ATE442349T1 (de) | Diacylglycerol-acyltransferase-hemmer | |
NO20084652L (no) | Deazapuriner anvendelige som inhibitorer av januskinaser | |
NO20084418L (no) | Azolopyridin-3-on derivater som inhibitorer av endoteliallipase | |
WO2010088518A3 (en) | Heterocyclic modulators of gpr119 for treatment of disease | |
ECSP066883A (es) | Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes | |
NO20083708L (no) | 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer | |
HK1124863A1 (en) | Inhibitors of sodium glucose co-transporter 2 and methods of their use | |
WO2008079610A3 (en) | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome | |
TNSN08531A1 (en) | Phenylacetic acid derivatives as cox - 2 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |